Febuxostat (ADENURIC®) is a potent, non-purine selective inhibitor of xanthine oxidase (XO), indicated for the treatment of hyperuricaemia (excess of uric acid) in patients suffering from gout and in adult patients at risk of tumour lysis syndrome.
This second indication was approved based on the success of the FLORENCE study, which enrolled 347 patients with lymphoma and leukemia, in 79 highly specialized centers for the treatment of hematological tumours. In this study Febuxostat, compared to the standard of care, showed a significant superiority in the control of uricaemia in intermediate/high risk adult patients with tumor lysis syndrome.
VISIT OUR CLINICAL TRIALS DATABASE